Liu L - Search Results

1

A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.

Varga A, Soria JC, Hollebecque A, LoRusso P, Bendell J, Huang SA, Wagle MC, Okrah K, Liu L, Murray E, Sanabria-Bohorquez SM, Tagen M, Dokainish H, Mueller L, Burris H. Varga A, et al. Among authors: liu l. Clin Cancer Res. 2020 Mar 15;26(6):1229-1236. doi: 10.1158/1078-0432.CCR-19-2574. Epub 2019 Dec 17. Clin Cancer Res. 2020. PMID: 31848189 Clinical Trial.

2

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.

Blake JF, Burkard M, Chan J, Chen H, Chou KJ, Diaz D, Dudley DA, Gaudino JJ, Gould SE, Grina J, Hunsaker T, Liu L, Martinson M, Moreno D, Mueller L, Orr C, Pacheco P, Qin A, Rasor K, Ren L, Robarge K, Shahidi-Latham S, Stults J, Sullivan F, Wang W, Yin J, Zhou A, Belvin M, Merchant M, Moffat J, Schwarz JB. Blake JF, et al. Among authors: liu l. J Med Chem. 2016 Jun 23;59(12):5650-60. doi: 10.1021/acs.jmedchem.6b00389. Epub 2016 Jun 7. J Med Chem. 2016. PMID: 27227380

3

Clinical responses to ERK inhibition in BRAF^V600E-mutant colorectal cancer predicted using a computational model.

Kirouac DC, Schaefer G, Chan J, Merchant M, Orr C, Huang SA, Moffat J, Liu L, Gadkar K, Ramanujan S. Kirouac DC, et al. Among authors: liu l. NPJ Syst Biol Appl. 2017 Jun 2;3:14. doi: 10.1038/s41540-017-0016-1. eCollection 2017. NPJ Syst Biol Appl. 2017. PMID: 28649441 Free PMC article.

4

Erratum: Clinical responses to ERK inhibition in BRAF^V600E-mutant colorectal cancer predicted using a computational model.

Kirouac DC, Schaefer G, Chan J, Merchant M, Orr C, Huang SA, Moffat J, Liu L, Gadkar K, Ramanujan S. Kirouac DC, et al. Among authors: liu l. NPJ Syst Biol Appl. 2017 Sep 4;3:25. doi: 10.1038/s41540-017-0026-z. eCollection 2017. NPJ Syst Biol Appl. 2017. PMID: 28879057 Free PMC article.

5

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.

Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy R, Coraggio M, Dong L, Eigenbrot C, Erickson R, Ghilardi N, Hau J, Katewa A, Kohli PB, Lee W, Lubach JW, McKenzie BS, Ortwine DF, Schutt L, Tay S, Wei B, Reif K, Liu L, Wong H, Young WB. Crawford JJ, et al. Among authors: liu l. J Med Chem. 2018 Mar 22;61(6):2227-2245. doi: 10.1021/acs.jmedchem.7b01712. Epub 2018 Feb 23. J Med Chem. 2018. PMID: 29457982

6

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.

Byrd JC, Smith S, Wagner-Johnston N, Sharman J, Chen AI, Advani R, Augustson B, Marlton P, Renee Commerford S, Okrah K, Liu L, Murray E, Penuel E, Ward AF, Flinn IW. Byrd JC, et al. Among authors: liu l. Oncotarget. 2018 Jan 22;9(16):13023-13035. doi: 10.18632/oncotarget.24310. eCollection 2018 Feb 27. Oncotarget. 2018. PMID: 29560128 Free PMC article.

7

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.

Byrd JC, Smith S, Wagner-Johnston N, Sharman J, Chen AI, Advani R, Augustson B, Marlton P, Commerford SR, Okrah K, Liu L, Murray E, Penuel E, Ward AF, Flinn IW. Byrd JC, et al. Among authors: liu l. Oncotarget. 2019 Jun 4;10(38):3827-3830. doi: 10.18632/oncotarget.27011. eCollection 2019 Jun 4. Oncotarget. 2019. PMID: 31217910 Free PMC article.

8

GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.

Cheung KWK, Yoshida K, Cheeti S, Chen B, Morley R, Chan IT, Sahasranaman S, Liu L. Cheung KWK, et al. Among authors: liu l. Drug Metab Dispos. 2019 Sep;47(9):966-973. doi: 10.1124/dmd.119.087924. Epub 2019 Jul 2. Drug Metab Dispos. 2019. PMID: 31266752 Clinical Trial.

9

Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer.

Malhi V, Agarwal P, Gates MR, Liu L, Wang J, De Bruyn T, Lam S, Eng-Wong J, Perez-Moreno P, Chen YC, Yu J. Malhi V, et al. Among authors: liu l. Cancer Res Commun. 2023 Dec 15;3(12):2551-2559. doi: 10.1158/2767-9764.CRC-23-0324. Cancer Res Commun. 2023. PMID: 38019116 Free PMC article. Clinical Trial.

10

Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.

Pei Z, Blackwood E, Liu L, Malek S, Belvin M, Koehler MF, Ortwine DF, Chen H, Cohen F, Kenny JR, Bergeron P, Lau K, Ly C, Zhao X, Estrada AA, Truong T, Epler JA, Nonomiya J, Trinh L, Sideris S, Lesnick J, Bao L, Vijapurkar U, Mukadam S, Tay S, Deshmukh G, Chen YH, Ding X, Friedman LS, Lyssikatos JP. Pei Z, et al. Among authors: liu l. ACS Med Chem Lett. 2012 Nov 29;4(1):103-7. doi: 10.1021/ml3003132. eCollection 2013 Jan 10. ACS Med Chem Lett. 2012. PMID: 24900569 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

68,454 results

Search Page